These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32535709)

  • 1. Behҫet-like syndrome associated with aplastic anemia successfully treated with mycophenolate mofetil.
    Krečak I; Šupe M; Ilić I; Gverić-Krečak V
    Ann Hematol; 2021 Sep; 100(9):2411-2413. PubMed ID: 32535709
    [No Abstract]   [Full Text] [Related]  

  • 2. Recovery of a dog from aplastic anaemia after treatment with mycophenolate mofetil.
    Yuki M; Sugimoto N; Otsuka H; Tanahashi S; Katoh M; Hirano T; Nishii N; Suzuki K
    Aust Vet J; 2007 Dec; 85(12):495-7. PubMed ID: 18042156
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of mycophenolate mofetil in treating patients with non responding aplastic anemia.
    Gan GG; Leong CF; Sangkar JV; Teh A; Goh KY; Cheong SK
    Med J Malaysia; 2005 Aug; 60(3):311-3. PubMed ID: 16379185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil: new applications for this immunosuppressant.
    Moder KG
    Ann Allergy Asthma Immunol; 2003 Jan; 90(1):15-19; quiz 20, 78. PubMed ID: 12546332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease.
    Kluger N; Poirier P; Guilpain P; Baixench MT; Cohen P; Paugam A
    Int J Infect Dis; 2009 Sep; 13(5):e325. PubMed ID: 19157948
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases.
    Shugaiv E; Tüzün E; Mutlu M; Kiyat-Atamer A; Kurtuncu M; Akman-Demir G
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S64-7. PubMed ID: 21968239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.
    Scheinberg P; Nunez O; Wu C; Young NS
    Br J Haematol; 2006 Jun; 133(6):606-11. PubMed ID: 16704434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression.
    Berman JA; Patel K; Caro J
    Am J Hematol; 2002 Sep; 71(1):64. PubMed ID: 12221685
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet's disease.
    Terashita S; Tanaka T; Taneichi H; Adachi Y; Mori M
    Pediatr Int; 2019 Sep; 61(9):920-922. PubMed ID: 31512337
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of immunosuppressives in Behçet's syndrome].
    Bonnet M
    Annee Ther Clin Ophtalmol; 1981; 32():89-111. PubMed ID: 7348139
    [No Abstract]   [Full Text] [Related]  

  • 13. An unusual case of Behçet's syndrome: triggered by typhoid vaccination?
    Molloy ES; Powell FC; Doran MF; Ryan JG; Mulligan NJ; McCarthy CJ; Keogan MT; McCarthy GM
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S71-4. PubMed ID: 15515791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualization of mycophenolate mofetil dose in renal transplant recipients.
    van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
    Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].
    Geilen CC; Orfanos-Boeckel H; Offermann G; Orfanos CE
    Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of mycophenolate mofetil in a child with refractory Evans syndrome.
    Guirat-Dhouib N; Mellouli F; Kouki R; Bejaoui M
    J Pediatr Hematol Oncol; 2010 Aug; 32(6):e244. PubMed ID: 20628320
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuro-Behçet's disease presenting with tumour-like lesions and responding to rituximab.
    Jade J; Chung K; Arendse M; Hussain Z; White D
    J Clin Neurosci; 2016 Oct; 32():139-41. PubMed ID: 27320374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycophenolate mofetil: an alternative treatment for refractory autoimmune hemolytic anemia in children].
    Navarro Mingorance A; Jimenez García I; Galera Miñarro AM; Fuster Soler JL
    An Pediatr (Barc); 2012 Jul; 77(1):64-5. PubMed ID: 22483537
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease.
    Adler YD; Mansmann U; Zouboulis CC
    Dermatology; 2001; 203(4):322-4. PubMed ID: 11752821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aplastic anemia combined with an autoimmune disease (eosinophilic fasciitis or glomerulonephritis)].
    Stebler C; Tichelli A; Gratwohl A; Dazzi H; Nissen C; Steiger U; Speck B
    Schweiz Med Wochenschr; 1991 Jun; 121(23):873-6. PubMed ID: 1857945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.